[Skip to Content]
[Skip to Content Landing]
Article
January 1960

Cessation of Systemic Steroids for Ocular Diseases

Author Affiliations

Atlanta
Clinical Investigator, Veterans Administration Hospital, Atlanta, Georgia, and Instructor Department of Medicine, Emory University School of Medicine (Dr. Ward).; Resident, Department of Ophthalmology, Grady Memorial Hospital, on rotation to Veterans Administration Hospital, Atlanta, Georgia. Present address: Suite 1006, Merchant's National Bank Bldg. Mobile, Alabama (Dr. De Juan).

AMA Arch Ophthalmol. 1960;63(1):140-142. doi:10.1001/archopht.1960.00950020142022
Abstract

Introduction  The use of systemic corticosteroids in the treatment of certain infectious and allergic diseases of the eye has been of great value in the last ten years. Since most of the conditions for which systemic steroids are used by ophthalmologists are self-limited, the problems which arise upon cessation of therapy are of importance very frequently.In the past decade numerous modifications of cortisone have been synthesized to obtain a compound of high anti-inflammatory activity disassociated from other pharmacologic actions. These newer compounds are used systemically by ophthalmologists widely. With mineralcorticoid activity reduced to a minimum, newer steroids can be used for prolonged periods of time without as much electrolyte derangement as previously. A large body of experimental evidence reviewed by Sayers1 suggests that the level of circulating adrenocortical hormone is an important factor in regulating the rate of discharge of corticotropin (ACTH) from the pituitary gland. Sayers and

First Page Preview View Large
First page PDF preview
First page PDF preview
×